#clinical-data

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

Immatics presented encouraging clinical data for its PRAME-targeted therapies at the ESMO Annual Meeting. The results demonstrated strong anti-tumor activity and a favorable safety profile across multiple advanced solid tumor indications.